MONTREAL--(BUSINESS WIRE)--Dec. 21, 2005--ProMetic Life Sciences Inc. (TSX:PLI.SV) (the “Company”) announced today that it intends to enter into a securities purchase agreement which provides for a private placement of senior secured convertible notes with US-based institutional investors in the aggregate principal amount of US$11.2 million for aggregate proceeds of US$8.9 million. The closing of the financing is currently scheduled for Thursday December 22, 2005. Net proceeds from the financing will be used for general corporate purposes.
